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Abstract
Introduction: Hepatologists and internists often encounter patients with unexplained high serum ferritin
concentration. After exclusion of hereditary hemochromatosis and hemosiderosis, rare disorders like hereditary
hyperferritinemia cataract syndrome should be considered in the differential diagnosis. This autosomal dominant
syndrome, that typically presents with juvenile bilateral cataracts, was first described in 1995 and has an increasing
number of recognized molecular defects within a regulatory region of the L-ferritin gene (FTL).
Case presentation: Two patients (32 and 49-year-old Caucasian men) from our ambulatory clinic were suspected
as having this syndrome and a genetic analysis was performed. In both patients, sequencing of the FTL 5’ region
showed previously described mutations within the iron responsive element (FTL c.33 C > A and FTL c.32G > C).
Conclusion: Hereditary hyperferritinemia cataract syndrome should be considered in all patients with unexplained
hyperferritinemia without signs of iron overload, particularly those with juvenile bilateral cataracts. Liver biopsy and
phlebotomy should be avoided in this disorder.
Introduction
Hereditary hyperferritinemia cataract syndrome (HHCS)
is a rare autosomal dominant genetic disease, which was
first described in 1995 independently by the groups of
Bonneau [1] and of Girelli [2]. They reported two
families in whom elevated serum L-ferritin concentra-
tion without iron overload, presenting with juvenile
bilateral cataracts, was inherited as an autosomal domi-
nant trait [1,2]. Cataracts comprise crystalline deposits
of L-ferritin. The underlying molecular defect in both
the early reports of HHCS was identified as point muta-
tions in the 5’ untranslated region (5’UTR) of the L-fer-
ritin gene (FTL), in the region corresponding to the
iron-responsive element (IRE) of L-ferritin messenger
ribonucleic acid (mRNA) [3,4]. These mutations lead to
loss of suppression of L-ferritin mRNA translation by
the iron-dependent iron regulatory protein (IRP) leading
to dysregulated expression of the L-ferritin protein.
Since these early reports, a series of other point muta-
tions and short deletions of L-ferritin IRE associated
with HHCS have been reported.
In 2000, Rososchova et al. measured serum ferritin
concentrations in 135 Swiss patients with bilateral oper-
ated cataracts before the age of 51 to detect HHCS.
However, no patients with HHCS were identified. This
led those authors to postulate that HHCS is so rare that
it might not exist in Switzerland [5]. We describe, to the
best of our knowledge, the first two cases of HHCS in
Switzerland, both with proven mutations in FTL. We
also review key aspects of the metabolism of cellular
iron and ferritin synthesis and we discuss the pathophy-
siology of HHCS.
Case presentations
Patient 1
A 32-year-old Caucasian man from Switzerland was
referred for further evaluation of an elevated serum fer-
ritin, the test for which was ordered because of tired-
ness. His serum ferritin concentration at presentation
was markedly elevated at 1314 μg/L (normal range 30-
400 μg/L), but the serum transferrin saturation of 23.3%
was within our laboratory reference interval (normal
range 15-50%).
Our patient had no history of alcohol abuse or other
metabolic diseases and no family history of hereditary
hemochromatosis (HH). Clinical examination revealed
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no abnormalities. Further laboratory evaluation showed
normal liver enzymes and normal hematological
parameters.
Genetic tests for HH showed a heterozygous H63D
substitution in the HFE gene but wild-type sequence at
the HFE C282Y locus. The histology of a liver biopsy
specimen was normal, and did not show iron accumula-
tion or steatosis. Together, these findings exclude a
diagnosis of HH.
Upon further evaluation, our patient revealed a history
of bilateral cataracts at four years of age. His mother,
his maternal aunt and maternal grandfather had all had
nuclear cataracts at an early age (Figure 1). Slit-lamp
examination, direct illumination and retro-illumination
of his lenses showed scattered, radially oriented flecks
and crystalline deposits in both lenses (Figure 2).
Sequencing of the FTL gene using a previously
described method [6] showed a heterozygous c.33 C > A
transversion in the IRE within the FTL 5’UTR. This
mutation has been previously associated with the HHCS
phenotype [6].
Patient 2
A 49-year-old Caucasian man was referred to our
department for further examination of a markedly ele-
vated serum ferritin concentration, of 2012 μg/L (nor-
mal range 30-400 μg/L). This had been identified as an
incidental finding during the investigation of an allergy.
His serum transferrin saturation of 29% was within the
normal range. His liver enzymes and hematological eva-
luation were normal. The HFE gene showed wild-type
sequence and an abdominal ultrasound showed normal
liver echotexture. Our patient reported bilateral lens
replacements 20 years ago due to bilateral juvenile cat-
aracts. His family history was not available because he
was an orphan. Deoxyribonucleic acid (DNA)
sequencing of the FTL 5’UTR revealed a heterozygous
c.32G > C transversion. This mutation is also known to
be associated with the clinical phenotype of HHCS [7].
Discussion
Hereditary hemochromatosis (HH) is the most frequent
treatable cause of hereditary iron overload in Caucasian
patients (homozygosity in three to five out of a thou-
sand). Since the initial manifestations of HH are fre-
quently non-specific (for example tiredness and
arthritis), serum ferritin is a frequently requested inves-
tigation in otherwise healthy patients. In some countries,
measuring serum ferritin concentration has been pro-
posed as a method of large-scale screening for HH, as
iron overload in this disorder can be effectively con-
trolled with phlebotomy if diagnosed before the onset of
liver cirrhosis.
In our patients the reasons for requesting serum ferri-
tin tests could not readily be explained. A high ferritin
value and a normal transferrin saturation in an other-
wise healthy young adult virtually excludes iron over-
load. In recent years, other rare disorders with or
without late onset iron overload have been described
and must be considered. One such disorder is autosomal
dominant type A ferroportin disease, which presents
with a low or slightly elevated transferrin saturation and
tissue iron overload. Additionally, a number of rare
autosomal recessive disorders causing iron overload are
recognized, including aceruloplasminemia and atransfer-
rinemia, which was first described in 1961 [8]. Both dis-
orders are characterized by microcytic anemia and
variable transferrin saturations. Aceruloplasminemia or
hypoceruloplasminemia have additional features such as
diabetes and neurological symptoms, such as cerebellar
ataxia, dementia or extrapyramidal symptoms. None of
these disorders of iron metabolism are associated with
congenital or juvenile nuclear cataracts, which is a
unique feature of HHCS.
Figure 1 Pedigree of the Patient 1. Pedigree of patient 1. (circles
- females, squares - males, black - affected members, red - patient 1)
Figure 2 Slit-lamp examination of the Patient 1.
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In healthy individuals, the serum ferritin concentration
correlates well with body iron stores. Serum ferritin is a
byproduct of intracellular ferritin synthesis [9]. Ferritin
is arranged in a particular way in order to create a cavity
capable of storing up to 4500 Fe3+ ions as an inorganic
complex [10,11]. As an intracellular iron storage mole-
cule, it is a heteropolymer composed of 24 H and L sub-
units, variously assembled. Serum ferritin, on the other
hand, consists mainly of L subunits, which can also be
glycosylated (G).
The three different subunits composing the proteinous
shell of human ferritin, L, H and G, arrange to form dif-
ferent isoferritins. The intracellular ferritin contains
mostly L and H subunits. Serum ferritin consists of L
and G subunits [3,10]. Ferritin synthesis is regulated by
the availability of iron. An interaction between the IRP
and the IRE of the FTL gene controls the translation of
the L-ferritin gene. The IRE is a non-coding stem loop
sequence located on the 5’UTR of the L-ferritin mRNA.
In the presence of abundant cellular iron there is a
structural change in the IRP, that prevents the IRP from
binding to the IRE, and ferritin synthesis will proceed.
When there is a shortage of cellular iron, there is no
relevant structural change and IRP binds to IRE and fer-
ritin translation is inhibited [1,11-14].
In 1995, Bonneau et al. speculated that the reason for
the accumulation of L-ferritin in HHCS is a mutation
on the IRE coding region of L-ferritin [1]. In 1995, two
groups in Italy and France simultaneously described the
first two point mutations in the IRE of L-ferritin gene
[3,4]. These mutations all change the structure of the
IRE in a way which reduces or abolishes binding to the
IRP. This leads to unregulated translation of the L-ferri-
tin gene and consequently elevated levels of circulating
L-ferritin [1,3,12,14,15].
Direct DNA sequencing was initially used to identify
mutations in FTL and most of the know mutations are
still detected by direct DNA sequencing. Another, faster
method is double-gradient denaturing gradient gel elec-
trophoresis, which is able to detect the mutations in a
single run [6,16].
A distinguishing feature of HHCS is bilateral juvenile
cataracts, which have an unusual morphology. They are
described as “sunflower-type” morphology or “bread-
crumb-like” [14]. The opacities consist of abundant L-
ferritin protein. The precise mechanism by which this
occurs is unclear. Lens opacities might be caused by a
yet unknown interaction between L-ferritin and the lens
proteins, or by a disturbed metabolism of L-ferritin
within the lens [17]. The high protein concentration in
the lens, the slow turnover of mature lens fibers after
formation and the surrounds of the avascular lens may
also be involved in the interaction. No involvement of
organs other than the eye has been reported in patients
so far [18]. Ferritin levels in HHCS can exceed values
over 6000 μg/L without any correlation to the severity
of the affected lens.
The prevalence of HHCS in different populations is
unknown. A number of reports, mostly case reports,
have previously been published [2,3,9,11,12,14,15].
In 2000 Rosochova et al. postulated that there were
no HHCS cases in Switzerland. Over four years, between
1995 and 1998, 3000 patients with cataract operations
were screened for HHCS. 135 patients were younger
than 51 years and 19 of these had nuclear cataracts. In
15, serum ferritin and transferrin saturation could be
measured. In two cases with elevated serum ferritin
level (267 μg/L and 416 μg/L) and a positive family his-
tory for cataracts, further genetic analysis for HHCS was
performed. DNA sequencing of the 5’UTR of L-Ferritin
mRNA showed a normal nucleotide sequence in the
whole region in both patients [5].
Conclusion
We describe two unrelated patients in Switzerland with
confirmed HHCS. High ferritin values in the absence of
liver disease or any other disease, together with nuclear
bilateral juvenile cataracts with or without a family his-
tory for juvenile cataracts, prompted this diagnosis. It is
important to inform the patient and his or her family
about the disease in order to prevent further evaluation
for iron overload. Genetic confirmation should be
obtained except in typical cases. Typical cases with
otherwise unexplained hyperferritinemia presenting with
autosomal dominant juvenile cataracts can be adequately
diagnosed with a medical history and biochemical ana-
lyses. Nuclear cataracts can be treated with lens replace-
ment therapy.
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